Table 1.
Association between expression levels of PRDM3 and clinical relevance in patients with PDAC (n = 94).
| Characteristics | Low expression (n = 62) | High expression (n = 32) | p-valuea |
|---|---|---|---|
| Histological grade | <0.001 | ||
| Poorly differentiated | 19 | 1 | |
| Moderately differentiated | 43 | 14 | |
| Well differentiated | 0 | 17 | |
| Survivalb | 0.030 | ||
| Alive | 17 | 16 | |
| Death | 45 | 16 | |
| Age (years) | 0.057 | ||
| >60 | 24 | 19 | |
| ≤60 | 38 | 13 | |
| Gender | 0.174 | ||
| Female | 22 | 16 | |
| Male | 40 | 16 | |
| Tumor size (cm) | 0.300 | ||
| ≤2.0 | 10 | 8 | |
| >2.0 | 52 | 24 | |
| Location | 0.333 | ||
| Head | 50 | 23 | |
| Body and tail | 12 | 9 | |
| TNMc | 0.717 | ||
| I, II | 54 | 27 | |
| III, IV | 8 | 5 | |
| CA19-9 | 0.526 | ||
| ≤35 | 12 | 8 | |
| >35 | 50 | 24 |
ap-values were based on t-test (two-sided). p < 0.05 was considered as statistically significant.
bAll PDAC patients received surgical resection without preoperative chemotherapy; median follow-up was 12.1 months after surgical resection; median survival time for patients deceased was 8.0 months; median follow-up for patients alive was 26.4 months.
cThe tumor-node-metastasis (TNM) stages were determined according to the 7th edition TNM classification of the American Joint Committee on Cancer.
Bold values indicate a statistically significant difference with a p-value less than 0.05.